Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi

IBSE:ONCSM Stock Report

Market Cap: ₺5.1b

Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi Past Earnings Performance

Past criteria checks 3/6

Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi's earnings have been declining at an average annual rate of -36.9%, while the Medical Equipment industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 19.9% per year. Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi's return on equity is 6.6%, and it has net margins of 4.3%.

Key information

-36.93%

Earnings growth rate

-152.83%

EPS growth rate

Medical Equipment Industry Growth12.30%
Revenue growth rate19.87%
Return on equity6.62%
Net Margin4.28%
Last Earnings Update30 Jun 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

IBSE:ONCSM Revenue, expenses and earnings (TRY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 25503221240
31 Mar 2545011260
31 Dec 24374-591250
30 Sep 24421-811460
30 Jun 24386-1521460
31 Mar 24366-1581330
31 Dec 23347-1151170
30 Sep 23436-1391290
30 Jun 23398-641050
31 Mar 23333-31820
31 Dec 22293-21660
30 Sep 2217393270
31 Dec 2112872160

Quality Earnings: ONCSM has high quality earnings.

Growing Profit Margin: ONCSM became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ONCSM has become profitable over the past 5 years, growing earnings by -36.9% per year.

Accelerating Growth: ONCSM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ONCSM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.9%).


Return on Equity

High ROE: ONCSM's Return on Equity (6.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/31 18:43
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.